��������

Mark Bagnall currently serves as CEO of Phenomix Sciences, Inc. Mark is an entrepreneur and business manager in the healthcare industry. He has held roles as CEO, COO and CFO during his career and has served on the boards of several public and private biotechnology companies. In the past 6 years, Mark has co-founded three start-ups and has advised and invested in several others.

Before Phenomix, Mark worked with Health2047, the innovation subsidiary of the AMA, most recently as an Executive-in-Residence. In that role, he identified and evaluated new business opportunities, including Health2047’s evaluation of Phenomix Sciences. Prior to joining Health2047, Mark co-founded and served as COO of Naia Rare Diseases, a company focused rare gastrointestinal disorders. Naia Rare Diseases was sold to 9 Meters Biopharma in May 2020. Prior to founding Naia, Mark served as CEO of GenturaDx until its successful sale to Luminex Corporation in 2012. GenturaDx’s technology is the basis of Luminex’s acclaimed “Aries” platform. Before GenturaDx, Mark held senior management positions in the biotechnology industry for almost 20 years. During his career, Mark has negotiated and managed six M&A transactions, raised more than $1/2 billion in equity and debt financings, and negotiated numerous licensing agreements. He is a CPA and started his career in the high technology and biotechnology practices of Ernst & Young.